RESUMO
RATIONALE: Knee osteoarthritis (KOA) is a chronic joint degenerative disease. Intra-articular injection (IAI) of hyaluronic acid (HA) is widely used to treat KOA. However, some HA injections have no effect at all. Polynucleotides (PN) are recently noted as a valid substitute for HA. PATIENT CONCERNS: A 61-year-old female was admitted to the pain center with symptoms of pain over the knee and warmth feeling with stiffness in the left knee. The patient reported chronic severe pain in the left knee area despite 6 times IAI of HA. She had past medical history of breast cancer and thyroid cancer. DIAGNOSES: She was diagnosed as having KOA. INTERVENTIONS: Ultrasound-guided IAI of PN was carried out 3 times in 3 weeks. OUTCOMES: She was followed-up for more than 5 months with good improvement in intractable knee pain without any adverse event. LESSONS: IAI of PN is an efficient therapeutic option for KOA treatment if HA injection is unsuccessful.
Assuntos
Osteoartrite do Joelho/terapia , Polinucleotídeos/administração & dosagem , Feminino , Humanos , Injeções Intra-Articulares , Pessoa de Meia-Idade , Polinucleotídeos/uso terapêutico , Amplitude de Movimento Articular , Ultrassonografia de IntervençãoRESUMO
Vaccination with antigen-pulsed CD40-activated B (CD40-B) cells can efficiently lead to the in vivo differentiation of naive CD8+ T cells into fully functional effectors. In contrast to bone marrow-derived dendritic cell (BMDC) vaccination, CD40-B cell priming does not allow for memory CD8+ T-cell generation but the reason for this deficiency is unknown. Here, we show that compared to BMDCs, murine CD40-B cells induce lower expression of several genes regulated by T-cell receptor signaling, costimulation, and inflammation (signals 1-3) in mouse T cells. The reduced provision of signals 1 and 2 by CD40-B cells can be explained by a reduction in the quality and duration of the interactions with naive CD8+ T cells as compared to BMDCs. Furthermore, CD40-B cells produce less inflammatory mediators, such as IL-12 and type I interferon, and increasing inflammation by coadministration of polyriboinosinic-polyribocytidylic acid with CD40-B-cell immunization allowed for the generation of long-lived and functional CD8+ memory T cells. In conclusion, it is possible to manipulate CD40-B-cell vaccination to promote the formation of long-lived functional CD8+ memory T cells, a key step before translating the use of CD40-B cells for therapeutic vaccination.
Assuntos
Linfócitos B/imunologia , Células da Medula Óssea/imunologia , Linfócitos T CD8-Positivos/imunologia , Inflamação/imunologia , Polinucleotídeos/administração & dosagem , Animais , Linfócitos B/transplante , Antígenos CD40/metabolismo , Ligante de CD40/genética , Ligante de CD40/metabolismo , Diferenciação Celular , Células Cultivadas , Técnicas de Cocultura , Fibroblastos/imunologia , Fibroblastos/metabolismo , Fator Estimulador de Colônias de Granulócitos e Macrófagos/imunologia , Humanos , Memória Imunológica , Interleucina-4/imunologia , Ativação Linfocitária , Camundongos , Camundongos Endogâmicos C57BL , Poli I-C , VacinaçãoRESUMO
The magnesium pyrophosphate particle (MgPP) is a unique and safe carrier that is prepared by simply mixing magnesium chloride and sodium pyrophosphate. In this study, we investigated whether MgPP can be used to deliver nucleic acid-based adjuvants to immune cells. Polyriboinosinic-polyribocytidylic acid (polyI:C), a ligand for toll-like receptor 3, was selected as a model nucleic acid-based adjuvant. PolyI:C-loaded MgPP (polyI:C-MgPP) was prepared by adding polyI:C during the MgPP preparation process. Efficient loading of polyI:C into MgPP was confirmed by measuring the absorbance at 260 nm after disruption of polyI:C-MgPP by ethylenediaminetetraacetic acid. Scanning electron microscopy revealed that both MgPP and polyI:C-MgPP had a unique sponge-like shape with a diameter of approximately 1 µm. PolyI:C-MgPP was more efficiently taken up by toll-like receptor 3-positive RAW264.7 cells than naked polyI:C, and its uptake stimulated increased tumor necrosis factor-α production. When the presentation of ovalbumin (OVA), a model antigen, was evaluated after the addition of OVA along with naked polyI:C or polyI:C-MgPP to mouse dendritic DC2.4 cells, polyI:C-MgPP substantially increased OVA presentation. These results indicate that MgPP is a useful delivery vehicle for polyI:C and that polyI:C-MgPP is an effective immune cell adjuvant.
Assuntos
Adjuvantes Imunológicos/administração & dosagem , Células Dendríticas/efeitos dos fármacos , Difosfatos/administração & dosagem , Compostos de Magnésio/administração & dosagem , Microesferas , Polinucleotídeos/administração & dosagem , Adjuvantes Imunológicos/metabolismo , Animais , Sobrevivência Celular/efeitos dos fármacos , Sobrevivência Celular/fisiologia , Células Dendríticas/imunologia , Células Dendríticas/metabolismo , Difosfatos/metabolismo , Compostos de Magnésio/metabolismo , Camundongos , Poli I-C , Polinucleotídeos/metabolismo , Receptor 3 Toll-Like/imunologia , Receptor 3 Toll-Like/metabolismoRESUMO
Polynucleotides are anionic macromolecules which are expected to transfer into the targeted cells through specific uptake mechanisms. So, we developed polynucleotides coating complexes of plasmid DNA (pDNA) and polyethylenimine (PEI) for a secure and efficient gene delivery system and evaluated their usefulness. Polyadenylic acid (polyA), polyuridylic acid (polyU), polycytidylic acid (polyC), and polyguanylic acid (polyG) were examined as the coating materials. pDNA/PEI/polyA, pDNA/PEI/polyU, and pDNA/PEI/polyC complexes formed nanoparticles with a negative surface charge although pDNA/PEI/polyG was aggregated. The pDNA/PEI/polyC complex showed high transgene efficiency in B16-F10 cells although there was little efficiency in pDNA/PEI/polyA and pDNA/PEI/polyU complexes. An inhibition study strongly indicated the specific uptake mechanism of pDNA/PEI/polyC complex. Polynucleotide coating complexes had lower cytotoxicity than pDNA/PEI complex. The pDNA/PEI/polyC complex showed high gene expression selectively in the spleen after intravenous injection into mice. The pDNA/PEI/polyC complex showed no agglutination with erythrocytes and no acute toxicity although these were observed in pDNA/PEI complex. Thus, we developed polynucleotide coating complexes as novel vectors for clinical gene therapy, and the pDNA/PEI/polyC complex as a useful candidate for a gene delivery system.
Assuntos
DNA/administração & dosagem , DNA/química , Técnicas de Transferência de Genes , Vetores Genéticos/química , Plasmídeos/administração & dosagem , Polinucleotídeos/química , Animais , Linhagem Celular Tumoral , Eritrócitos/efeitos dos fármacos , Eritrócitos/metabolismo , Expressão Gênica , Técnicas de Transferência de Genes/efeitos adversos , Terapia Genética , Vetores Genéticos/administração & dosagem , Vetores Genéticos/efeitos adversos , Camundongos , Nanopartículas/administração & dosagem , Nanopartículas/química , Tamanho da Partícula , Plasmídeos/química , Polietilenoimina/administração & dosagem , Polietilenoimina/química , Polinucleotídeos/administração & dosagem , Polinucleotídeos/efeitos adversos , Baço/metabolismo , Eletricidade Estática , Propriedades de SuperfícieRESUMO
Based on previously reported antiproliferative activity screening, four most promising disubstituted 2-phenylbenzothiazole hydrochlorides were chosen for detailed study. Water solubility, as well as liphophilicity/hydrophilicity balance of organic core were modified by conversion to mesylate salts. For purpose of structure/activity studies their structures were determined by X-ray structure analysis. Detailed analysis of interactions of new compounds with double stranded (ds-) DNA/RNA by UV/Vis and CD titrations, thermal melting and viscometry experiments revealed that most of studied compounds intercalate into ds-RNA but bind into minor groove of AT-DNA, and agglomerate along GC-DNA. Furthermore, compounds also interact with ss-RNA, but only amino-imidazolinyl 2-phenylbenzothiazole, 4b displayed well defined orientation and dominant binding mode (by induced CD signals) with poly A and poly G. Besides, in vitro investigations revealed moderate to high antiproliferative activity of benzothiazoles against seven human cancer cell lines, while in some cases (HTC 116, SW620, MIA PaCa-2) high correlation between the type of the amidino group and cytotoxic activity was observed.
Assuntos
Antineoplásicos/farmacologia , Benzotiazóis/farmacologia , Mesilatos/farmacologia , Polinucleotídeos/farmacologia , Animais , Antineoplásicos/administração & dosagem , Antineoplásicos/química , Benzotiazóis/síntese química , Benzotiazóis/química , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Cristalografia por Raios X , Relação Dose-Resposta a Droga , Ensaios de Seleção de Medicamentos Antitumorais , Células HeLa , Humanos , Células MCF-7 , Masculino , Mesilatos/síntese química , Mesilatos/química , Camundongos , Camundongos Endogâmicos BALB C , Modelos Moleculares , Estrutura Molecular , Polinucleotídeos/administração & dosagem , Polinucleotídeos/química , Relação Estrutura-AtividadeRESUMO
Alternatives to efficient viral vectors in gene therapy are desired because of their poor safety profiles. Chitosan is a promising non-viral nucleotide delivery vector because of its biocompatibility, biodegradability, low immunogenicity and ease of manufacturing. Since the transfection efficiency of chitosan polyplexes is relatively low compared to viral counterparts, there is an impetus to gain a better understanding of the structure-performance relationship. Recent progress in preparation and characterisation has enabled coupling analysis of chitosans structural parameters that has led to increased TE by tailoring of chitosan's structure. In this review, we summarize the recent advances that have lead to a more rational design of chitosan polyplexes. We present an integrated review of all major areas of chitosan-based transfection, including preparation, chitosan and polyplexes physicochemical characterisation, in vitro and in vivo assessment. In each, we present the obstacles to efficient transfection and the strategies adopted over time to surmount these impediments.
Assuntos
Quitosana/química , Ácidos Nucleicos/administração & dosagem , Animais , Terapia Genética , Humanos , Ácidos Nucleicos/química , Polinucleotídeos/administração & dosagem , Polinucleotídeos/química , Transfecção/métodosRESUMO
Cationic polyrotaxanes, obtained by temperature activated threading of cationic cyclodextrin derivatives onto water-soluble cationic polymers (ionenes), form metastable nanometric polyplexes with pDNA and combinations of siRNA with pDNA. Because of their low toxicity, the polyrotaxane polyplexes constitute a very interesting system for the transfection of polynucleotides into mammalian cells. The complexation of Cy3-labeled siRNA within the polyplexes was demonstrated by fluorescence correlation spectroscopy. The uptake of the polyplexes (red) was imaged by confocal fluorescence microscopy using the A549 cell line as a model (blue: nuclei, green: membranes). The results prove the potential of polyrotaxanes for further investigations involving knocking down genes of therapeutic interest.
Assuntos
Ciclodextrinas/química , Portadores de Fármacos/química , Polinucleotídeos/administração & dosagem , Rotaxanos/química , Cátions , Linhagem Celular , Ciclodextrinas/síntese química , DNA/administração & dosagem , DNA/genética , Portadores de Fármacos/síntese química , Endocitose , Inativação Gênica , Humanos , Luciferases/genética , Espectroscopia de Ressonância Magnética , Microscopia Confocal , Microscopia de Fluorescência , Tamanho da Partícula , Plasmídeos/administração & dosagem , Plasmídeos/genética , Polinucleotídeos/genética , RNA Interferente Pequeno/administração & dosagem , RNA Interferente Pequeno/genética , Rotaxanos/síntese química , Espectrometria de FluorescênciaRESUMO
This randomized, double-blind clinical trial was conducted over 16 weeks to assess the efficacy and safety profile of intra-articular polynucleotides gel injections in the treatment of knee osteoarthritis associated with persistent knee pain. 60 patients were enrolled and randomized to receive intra-articular polynucleotides (n = 30) or hyaluronan (n = 30); patients received five weekly intra-articular knee injections and the follow-up period was 3 months after the end of treatment. Primary endpoint was to determine polynucleotides (PN) efficacy in reducing knee pain at the end of the study, over baseline value and over standard hyaluronan viscosupplementation (HA). Pain levels were measured using a 0-10 cm Visual Analogue Scale (VAS). Secondary endpoints included Knee Osteoarthritis Outcome Score (KOOS), NSAIDs consumption, crackling during movement and articular mobility limitation. The mean global VAS pain decreased from 5.7 + or - 1.9 cm (T0) to 1.9 + or - 1.5 cm (T16) in polynucleotide group and from 4.9 + or - 2.0 cm (T0) to 2.1 + or - 1.4 cm (T16) in hyaluronan group. The reduction in pain was statistically significant for both groups. KOOS increases from baseline values were statistically significant in both groups. No significant adverse events were reported. These findings suggest that intra-articular polynucleotides can be a valid alternative to traditional hyaluronan supplementation for the treatment of knee osteoarthritis.
Assuntos
Artralgia/tratamento farmacológico , Ácido Hialurônico/administração & dosagem , Osteoartrite do Joelho/tratamento farmacológico , Polinucleotídeos/administração & dosagem , Viscossuplementos/administração & dosagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Método Duplo-Cego , Feminino , Humanos , Injeções Intra-Articulares , Masculino , Pessoa de Meia-Idade , Medição da Dor , Amplitude de Movimento Articular , Recuperação de Função FisiológicaRESUMO
Since the prognosis of patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) still remains poor, new relapse prevention strategies are needed. We evaluated the pre-immunization of mice with DNA-based vaccines subsequently challenged by the syngeneic Ph+ ALL cell line BM185. Ballistic transfer of minimalistic immunogenically defined gene expression (MIDGE) vectors encoding a BCR-ABLp185 fusion specific peptide or GM-CSF were used for in vivo transfection. DNA-based double stem-loop immunomodulators (dSLIM) were used as immune adjuvant. We present survival and functional data that DNA-based vaccination with BCR-ABLp185 fusion specific sequences, GM-CSF and dSLIM leads to an anti-tumor effect in mice challenged with a lethal Ph+ ALL dose and this effect depends on leukaemia-specific sequences.
Assuntos
Vacinas Anticâncer/imunologia , Fatores Imunológicos/administração & dosagem , Polinucleotídeos/administração & dosagem , Leucemia-Linfoma Linfoblástico de Células Precursoras/imunologia , Leucemia-Linfoma Linfoblástico de Células Precursoras/prevenção & controle , Vacinas de DNA/imunologia , Animais , Linhagem Celular Tumoral , Feminino , Vetores Genéticos , Camundongos , Camundongos Endogâmicos BALB C , Leucemia-Linfoma Linfoblástico de Células Precursoras/patologia , Prevenção Secundária , Análise de Sobrevida , Transfecção/métodosRESUMO
Recent progress in recombinant gene technology and cell culture technology has made it possible to use protein and polynucleotides as effective drugs. However, because of their short half-lives in the body and the necessity of delivering to target site, those substances do not always exhibit good potency as expected. Therefore, delivery systems of such drugs are important research subjects in the field of pharmacology, and to prolong the effect of these drugs, many studies are being conducted to control the release of proteins and polynucleotides from various carrier materials. Collagen is one of the most useful carrier materials for this purpose. In this article, we report on the controlled release of protein drugs using collagen, focusing on a new drug delivery system (DDS), the Minipellet, as our basic technology. Then we introduce our recent work about gene therapy using collagen-based DDS. Basic formulation study showed that collagen DDS protects DNA degradation from both chemical cleavage and enzymatic digestion. A single injection of collagen DDS containing plasmid DNA produced physiologically significant levels of gene-encoding proteins in the local site and systemic circulation of animals and resulted in prolonged biological effects. These results suggest that collagen DDS containing plasmid DNA may enhance the clinical potency of plasmid-based gene transfer, facilitating a more effective and long-term use of naked plasmid vectors for gene therapy. Also, variety kinds of application of collagen DDS for gene therapy using adenovirus vector, antisense DNA and DNA vaccine, will be discussed.
Assuntos
Colágeno/química , Técnicas de Transferência de Genes , Polinucleotídeos/administração & dosagem , Polinucleotídeos/genética , Proteínas/administração & dosagem , Proteínas/genética , Implantes Absorvíveis , Animais , DNA Antissenso/administração & dosagem , Preparações de Ação Retardada/química , Portadores de Fármacos/química , Terapia Genética/métodos , Vetores Genéticos/administração & dosagem , Plasmídeos/administração & dosagem , Polinucleotídeos/biossíntese , Biossíntese de Proteínas , Vacinas de DNA/administração & dosagemRESUMO
Evaluation of immunotherapy strategies in mouse models of carcinoma is hampered by the limited number of known murine tumor antigens (Ags). Although tumor Ags can be identified based on cytotoxic T-cell activation, this approach is not readily accomplished for many tumor types. We applied an alternative strategy based on a humoral immune response, SEREX, to the identification of tumor Ags in the murine colon adenocarcinoma cell line MC38. Immunization of syngeneic C57BL/6 mice with MC38 cells by three different methods induced a protective immune response with concomitant production of anti-MC38 antibodies. Immunoscreening of an MC38-derived expression library resulted in the identification of the endogenous ecotropic leukemia virus envelope (env) protein and the murine ATRX protein as candidate tumor Ags. Northern blot analysis demonstrated high levels of expression of the env transcript in MC38 cells and in several other murine tumor cell lines, whereas expression in normal colonic epithelium was absent. ATRX was found to be variably expressed in tumor cell lines and in normal tissue. Further analysis of the expressed env sequence indicated that it represents a nonmutated tumor Ag. Polynucleotide immunization with DNA encoding the env polypeptide resulted in strong and specific antibody responses to this self Ag in all immunized mice. Thus, SEREX offers a rapid means of identifying tumor Ags in murine cancer models.
Assuntos
Adenocarcinoma/imunologia , Antígenos de Neoplasias/isolamento & purificação , DNA Helicases , Proteínas Nucleares , Adenocarcinoma/química , Animais , Anticorpos Antineoplásicos/biossíntese , Antígenos de Neoplasias/administração & dosagem , Antígenos de Neoplasias/imunologia , Sequência de Bases , Southern Blotting , Proteínas de Ligação a DNA/biossíntese , Proteínas de Ligação a DNA/genética , Modelos Animais de Doenças , Produtos do Gene env/biossíntese , Produtos do Gene env/genética , Produtos do Gene env/imunologia , Produtos do Gene env/isolamento & purificação , Técnica de Placa Hemolítica , Injeções Subcutâneas , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Camundongos Endogâmicos DBA , Dados de Sequência Molecular , Transplante de Neoplasias , Polinucleotídeos/administração & dosagem , Polinucleotídeos/imunologia , RNA Mensageiro/biossíntese , Análise de Sequência de DNA , Fatores de Transcrição/biossíntese , Fatores de Transcrição/genética , Células Tumorais Cultivadas/transplante , Proteína Nuclear Ligada ao XRESUMO
In preparation for a Phase I trial of DNA immunization against carcinoembryonic antigen (CEA) in patients with colorectal carcinoma, we have produced a single plasmid DNA encoding CEA and hepatitis B surface antigen (HBsAg) under transcriptional regulatory control of two separate cytomegalovirus promoters within separate eukaryotic expression cassettes, designated pCEA/HBsAg. Hepatitis B surface antigen was included to provide an internal positive control for the efficacy of this immunization strategy without regard to the issue of breaking tolerance to a self-antigen. In the present work, we sought to examine the immunogenicity of this plasmid in a nonhuman primate model with close phylogenetic relationship to humans. Groups of pig-tailed macaques were immunized with pCEA/ HBsAg by i.m. injection or particle bombardment of the skin according to a dose and schedule thought to be optimal for the respective technique of DNA immunization. Both administration techniques produced humoral and lympho-proliferative responses of comparable magnitude. However, delayed type hypersensitivity to CEA and CEA-specific interleukin-2 release were observed only in the i.m. group, suggesting a qualitative difference in the character of the immune response elicited by the two techniques of DNA immunization. The antibody responses to CEA and HBsAg were surprisingly persistent in that all immunized animals maintained moderate antibody titers against both antigens for more than 15 months after the last boost. No toxicity was observed during 2 years of follow-up, including no measurable levels of anti-DNA antibody. This antitumor immunization strategy is presently being examined in patients with metastatic colorectal carcinoma using pCEA/HBsAg administered by i.m. injection.
Assuntos
Vacinas Anticâncer/administração & dosagem , Antígeno Carcinoembrionário/imunologia , Polinucleotídeos/administração & dosagem , Vacinas de DNA/administração & dosagem , Animais , Anticorpos/sangue , Anticorpos/imunologia , Formação de Anticorpos/efeitos dos fármacos , Vacinas Anticâncer/imunologia , Vacinas Anticâncer/toxicidade , Feminino , Antígenos de Superfície da Hepatite B/imunologia , Imunidade Celular/efeitos dos fármacos , Imunização , Interleucina-2/metabolismo , Ativação Linfocitária , Macaca nemestrina , Polinucleotídeos/imunologia , Polinucleotídeos/toxicidade , Vacinas de DNA/imunologia , Vacinas de DNA/toxicidadeRESUMO
The novel observations that intramuscular injection of plasmid DNA preparations could result in myocyte gene expression and induce immune responses to encoded immunogens has generated intense interest in the form of gene therapy. This phenomena can occur with both DNA and RNA reagents, and can be used in immune protection (vaccine) or therapy strategies. Immunization with DNA plasmids has generated protective immunity to a wide variety of pathogens and tumor cells in murine animal models. Immune response has occurred in a broad range of animal species following intramuscular injection of plasmid DNA encoding various immunogens as well as following other routes of administration (intravenous, intradermal, etc). The mechanisms responsible for induction of the immune response are as yet unclear, but responses include antibody production, T-cell proliferation, lymphokine release, generation of cytolytic T cells, and delayed hypersensitivity reactions. Plasmid DNA production and purification methods are relatively easy to standardize, and dual expressing plasmids allow incorporation of immune enhancement molecules or second immunogens. Plasmid DNA encoding nontransforming tumor-associated antigens are in development with a National Institutes of Health-approved protocol for carcinoembryonic antigen in colorectal cancer patients. Transforming tumor-associated antigens (eg, HER2/neu) may be approached with RNA or replicative RNA constructs for immunization. The efficacy of this immune approach will soon be examined in clinical trials in patients with cancer and the acquired immunodeficiency syndrome.
Assuntos
Terapia Genética/métodos , Neoplasias/terapia , Plasmídeos/genética , Polinucleotídeos/administração & dosagem , Animais , Antígeno Carcinoembrionário/imunologia , Expressão Gênica , Humanos , ImunizaçãoAssuntos
Adenoviridae/genética , DNA Recombinante , Terapia Genética/métodos , Vetores Genéticos , Polinucleotídeos/administração & dosagem , Animais , Citomegalovirus/genética , DNA Recombinante/administração & dosagem , DNA Recombinante/genética , DNA Recombinante/farmacocinética , Genes Reporter , Vetores Genéticos/administração & dosagem , Vetores Genéticos/genética , Vetores Genéticos/farmacocinética , Globinas/genética , Hormônio do Crescimento/genética , Coração , Humanos , Injeções , Isoenzimas/biossíntese , Isoenzimas/genética , Camundongos , Miocárdio/enzimologia , Cadeias Pesadas de Miosina/biossíntese , Cadeias Pesadas de Miosina/genética , Miosinas/biossíntese , Miosinas/genética , Polinucleotídeos/genética , Regiões Promotoras Genéticas , Ratos , Proteínas Recombinantes de Fusão/biossíntese , Segurança , Transfecção/métodosRESUMO
Heparin is normally used for anticoagulation during cardiopulmonary bypass (CPB), but its use is contraindicated in patients with a history of heparin-induced thrombocytopenia, heparin-provoked thrombosis, or both. Heparin therapy can also be ineffective due to heparin resistance. A short-acting, oligonucleotide-based thrombin inhibitor (thrombin aptamer) may potentially serve as a substitute for heparin in these and other clinical situations. We tested a novel thrombin aptamer in a canine CPB pilot study to determine its anticoagulant efficacy, the resultant changes in coagulation variables, and the aptamer's clearance mechanisms and pharmacokinetics. Seven dogs were studied initially: Four received varied doses of the aptamer (to establish the pharmacokinetic profile) and 3 received heparin. Subsequently, 4 other dogs underwent CPB, receiving a constant infusion of the aptamer before CPB (to characterize the baseline coagulation status), with partial CPB and hemodilution, during 60 minutes of total CPB, and, finally, after a 2-hour recovery period. At a 0.5 mg.kg-1.min-1 dose, the activated clotting time rose with aptamer infusion from 106 +/- 12 seconds to 187 +/- 8 seconds (+/- 1 standard deviation) (p = 0.014), increased further with hemodilution (to 259 +/- 41 seconds; p = 0.017), and was even more prolonged during total CPB (> 1,500 seconds; p < 0.001). This later increase in the activated clotting time paralleled a rise in the plasma concentration of the thrombin aptamer during total CPB, as determined by high-performance liquid chromatography.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Ponte Cardiopulmonar , Oligonucleotídeos , Polinucleotídeos/administração & dosagem , Trombina/antagonistas & inibidores , Animais , Aptâmeros de Nucleotídeos , Coagulação Sanguínea , Cromatografia Líquida de Alta Pressão , Cães , Relação Dose-Resposta a Droga , Heparina/administração & dosagem , Infusões Intravenosas , Projetos Piloto , Polinucleotídeos/farmacocinética , Tempo de ProtrombinaRESUMO
Treatment of Wistar/AG rats with a single i.p. injection of 1 mg/kg of synthetic double-stranded polynucleotides, either polyadenylic-polyuridylic acid (rAn.rUn), or a mismatched analogue of polyinosinic-polycytidylic acid (rIn.r(C12U)n), enhanced the cytotoxicity of natural killer (NK) cells among peripheral blood leukocytes and lung intracapillary leukocytes (LICL). The enhancement reached a peak 24 h after treatment and returned to control values after 4 days. In rats given repeated injections of double-stranded polynucleotides (2 per week), the NK cytotoxicity expressed by LICL reached more than ten times (in lytic units) the control levels between day 8, after 3 injections, and day 360, after 100 injections. No hyporesponsiveness was observed. Moreover, NK activity was frequently and significantly higher in rats given multiple injections than in those given a single injection. In rats with experimentally induced P77 lung fibrohistiocytoma colonies, repeated injections of rIn.r(C12U)n stimulated NK activity and reduced the number of metastatic nodules from 172 to 19. The same significant reduction (from 172 to 27) was also observed in animals given repeated injections of rAn.rUn. However, with two models of spontaneous metastases, significant reduction in lung metastases (M37 bronchioloalveolar carcinoma) or lack of effect (S4T19 rhabdomyosarcoma) were observed.
Assuntos
Citotoxicidade Imunológica/efeitos dos fármacos , Gangliosídeo G(M1) , Células Matadoras Naturais/imunologia , Polinucleotídeos/farmacologia , Animais , Glicoesfingolipídeos/imunologia , Masculino , Metástase Neoplásica , Transplante de Neoplasias , Neoplasias Experimentais/imunologia , Polinucleotídeos/administração & dosagem , Ratos , Ratos EndogâmicosAssuntos
Fibrossarcoma/patologia , Interferons/farmacologia , Mitose/efeitos dos fármacos , Polinucleotídeos/farmacologia , Sarcoma Experimental/patologia , Animais , Contagem de Células , Divisão Celular/efeitos dos fármacos , Linhagem Celular , Meios de Cultura , Depressão Química , Relação Dose-Resposta a Droga , Fibrossarcoma/induzido quimicamente , Haplorrinos , Técnicas In Vitro , Interferons/administração & dosagem , Rim , Metilcolantreno , Camundongos , Polinucleotídeos/administração & dosagem , Fatores de TempoAssuntos
AMP Cíclico/efeitos adversos , Hipersensibilidade Tardia/tratamento farmacológico , Polinucleotídeos/efeitos adversos , Adenosina , Animais , Líquido Ascítico/citologia , Contagem de Células , AMP Cíclico/administração & dosagem , Dessensibilização Imunológica , Feminino , Cobaias , Hipersensibilidade Tardia/induzido quimicamente , Injeções Intradérmicas , Injeções Intraperitoneais , Contagem de Leucócitos , Linfócitos , Macrófagos , Polinucleotídeos/administração & dosagem , Testes CutâneosRESUMO
Enhancement of antibody formation in vitro and in vivo by poly(A.U), cyclic AMP, dibutyryl cyclic AMP, or any one of these agents in combination with theophylline or caffeine, is usually limited to certain dose ranges. High doses of these nonspecific stimulators can produce less or no enhancement, or may actually inhibit antibody formation. Such dose-response relationships may be pertinent to an understanding of phenomena of specific immunological nonresponsiveness and certain types of antigenic competition.